Quarterly report pursuant to Section 13 or 15(d)

Note 6 - Related Party Transactions (Details Textual)

v3.23.3
Note 6 - Related Party Transactions (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 09, 2017
Feb. 17, 2015
Sep. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Nov. 08, 2022
Feb. 28, 2015
Fortress [Member]              
Percentage of Fully-diluted Outstanding Equity             2.50%
Percentage of Equity or Debt Fnancing             2.50%
Percentage of Annual net Sales             4.50%
Shared Services Agreement, Amounts Reimbursable       $ 79,991      
Other Receivable, after Allowance for Credit Loss, Noncurrent     $ 13,229 $ 13,229      
Fortress [Member] | Management Services Agreement [Member]              
Term of Agreement (Year)   5 years          
Automatic Renewal Term of Agreement (Year)   5 years          
Annual Consulting Fee   $ 500,000          
Increase in Annual Consulting Fee   1,000,000          
Excess in Net Assets Value   $ 100,000,000          
Fortress [Member] | Avenue Baergic Founders Agreement [Member]              
Excess in Net Assets Value $ 100,000,000            
BaergicBio, Inc.[Member]              
Proceeds From Equity Fee         $ 10,500,000    
BaergicBio, Inc.[Member] | Founders Agreement and Management Services Agreement [Member]              
Percentage of Equity Fee           2.50%  
BaergicBio, Inc.[Member] | Avenue Baergic Founders Agreement [Member]              
Term of Agreement (Year) 5 years            
Annual Consulting Fee $ 500,000            
Increase in Annual Consulting Fee $ 1,000,000            
Percentage Of Additional Consideration Of Equity Fee         2.50%    
Percentage Considered For The Calculation Of One-Time Fee         4.50%    
Urica Therapeutics [Member]              
Shared Services Agreement, Amounts Reimbursable     $ 13,229